Eli Lilly and Co (Eli Lilly and Co) Interest Expense : $-486 Mil (TTM As of Dec. 2023)

View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Eli Lilly and Co's interest expense for the three months ended in Dec. 2023 was $ -138 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-486 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Eli Lilly and Co's Operating Income for the three months ended in Dec. 2023 was $ 3,540 Mil. Eli Lilly and Co's Interest Expense for the three months ended in Dec. 2023 was $ -138 Mil. Eli Lilly and Co's Interest Coverage for the quarter that ended in Dec. 2023 was 25.62. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Eli Lilly and Co Interest Expense Historical Data

The historical data trend for Eli Lilly and Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Interest Expense Chart

Eli Lilly and Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-400.60

-359.60

-339.80

-331.60

-485.90

Eli Lilly and Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-84.00	-102.80	-120.30	-124.60	-138.20

Eli Lilly and Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-486 Mil.

Eli Lilly and Co (NYSE:LLY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Eli Lilly and Co's Interest Expense for the three months ended in Dec. 2023 was $-138 Mil. Its Operating Income for the three months ended in Dec. 2023 was $3,540 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $18,321 Mil.

Eli Lilly and Co's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	3540	/	-138.2
	=	25.62

The higher the ratio, the stronger the company's financial strength is.

Eli Lilly and Co (Eli Lilly and Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

LLY:Mexico 1LLY:Italy LLY:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Switzerland LLY:Canada LILY34:Brazil LLYC:Austria LLY:Argentina

Address

Lilly Corporate Center, Indianapolis, IN, USA, 46285

Website

https://www.lilly.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Executives

Lilly Endowment Inc	10 percent owner	2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski	officer: Chief Accounting Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems	officer: SVP, ERM & CECO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson	officer: SVP and Pres., Lilly Bio-Meds	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White	officer: SVP & Pres-Lilly Oncology	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier	officer: EVP, HR & Diversity	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai	director
Mary Lynne Hedley	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van	officer: SVP, CEO LoxoONC, Pres LlyONC	C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau	officer: SVP & CIDO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez	officer: SVP & Pres., Mfg. Operations	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson	director	C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi	officer: SVP & CFO	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger	director	450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017